Maplight Therapeutics, INC

MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, meeting its primary endpoint and showing a favorable safety profile.

MapLight Therapeutics stockholders re-elected three directors and ratified the appointment of RSM US LLP as auditors.

MapLight Therapeutics announces the immediate separation of its CFO, Vishwas Setia, due to a human resources violation, appointing Jonathan Gillis as interim CFO.

MapLight Therapeutics reported Q1 2026 financial results, highlighting strong clinical trial momentum and a cash runway through 2027, with key data readouts expected mid-August 2026.

MapLight Therapeutics announced its Q4 and full year 2025 financial results, highlighted by a strong cash position, progress in multiple Phase 2 trials, and pipeline expansion.

MapLight Therapeutics announced an update to its Phase 2 clinical trial timelines for ML-007C-MA and ML-004, with topline results now expected in Q3 2026, alongside a strong cash position of approximately $450 million as of December 31, 2025.

MapLight Therapeutics, Inc. reported a net loss of $60.7 million for the first quarter of 2026, with increased R&D expenses driving the results.

MapLight Therapeutics, a clinical-stage biopharmaceutical company, successfully completed its initial public offering and concurrent private placement in October 2025, raising approximately $269.8 million in net proceeds to fund its central nervous system disorder pipeline through 2027.

MapLight Therapeutics reported a significant net loss in 2025 while progressing its lead CNS drug candidates, ML-007C-MA and ML-004, through Phase 2 clinical trials with key data expected in 2026 and 2027.

Catalyst4, Inc. reported changes in beneficial ownership of MapLight Therapeutics, Inc. common stock on July 28, 2026.

Troy Cox, a Director of MapLight Therapeutics, Inc., purchased 15,620 shares of common stock on July 28, 2026 for $9.52 per share.

Jonathan Gillis, CAO and Interim CFO of MapLight Therapeutics, Inc., sold 36,979 shares of common stock on July 15, 2026.

Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics, Inc., sold 36,284 shares of common stock on July 15, 2026.

Christopher A. Kroeger, Chief Executive Officer and a Director of MapLight Therapeutics, Inc., sold 147,639 shares of common stock on July 15, 2026.

James Woodruff Lillie, Chief Scientific Officer of MapLight Therapeutics, Inc., sold 18,267 shares of common stock on July 15, 2026.

MapLight Therapeutics, a clinical-stage biopharmaceutical company, is launching its initial public offering to fund the advancement of its central nervous system disorder pipeline, despite ongoing substantial losses and a 'going concern' warning.

Clinical-stage biopharmaceutical company MapLight Therapeutics files S-1 for initial public offering to advance CNS disorder therapies, including lead candidates for schizophrenia and Alzheimer's psychosis.

Catalyst4, Inc. and associated individuals have increased their beneficial ownership of MapLight Therapeutics, Inc. common stock by acquiring over 1.2 million shares in recent open market transactions.

Novo Holdings A/S has reduced its stake in Maplight Therapeutics, Inc. to below 5% following a series of open market sales.

Catalyst4, Inc. and its directors have reported a significant 45.1% beneficial ownership in MapLight Therapeutics, Inc. following its initial public offering and a concurrent private placement.

Novo Holdings A/S has filed a Schedule 13D, revealing an 8.4% beneficial ownership stake in Maplight Therapeutics, Inc. following its recent IPO.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7.4% of MapLight Therapeutics Inc.'s common stock as of March 31, 2026.

Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. have disclosed a 7.1% beneficial ownership stake in MapLight Therapeutics, Inc.